argenx SE (LON: 0QW0)

Market Cap	31.72B
Revenue (ttm)	1.42B
Net Income (ttm)	-30.06M
Shares Out	n/a
EPS (ttm)	-0.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Average Volume	15,634
Open	352.20
Previous Close	357.04
Day's Range	352.20 - 352.20
52-Week Range	314.70 - 494.00
Beta	0.27
RSI	55.22
Earnings Date	Feb 27, 2025

About argenx SE

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,148
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QW0

Financial Performance

In 2023, argenx SE's revenue was $1.27 billion, an increase of 187.66% compared to the previous year's $441.01 million. Losses were -$295.05 million, -58.42% less than in 2022.

Financial numbers in USD